Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri PML Cases Pose REMS Challenges To FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Two new cases of the brain infection could impact sales of the drug, particularly in the treatment naive multiple sclerosis setting.

You may also be interested in...



Tysabri Sales Dip But Don’t Swoon After PML Adverse Events

Biogen plans to report further progressive multifocal leukoencephalopathy cases only when “they provide substantial new information,” CEO Mullen says.

Tysabri Sales Dip But Don’t Swoon After PML Adverse Events

Biogen plans to report further progressive multifocal leukoencephalopathy cases only when “they provide substantial new information,” CEO Mullen says.

PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter

Finding follows reports of PML in Rituxan, Tysabri patients earlier this year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel